ProShares Trust - ProShares Russell 2000 Div Growers ETF
SMDV
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $27.84 Billion |
|---|---|
| Enterprise Value | $27.66 Billion |
| Dividend Yield | $1.73 (2.30%) |
| Earnings per Share | $- |
| Beta | 0.82 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2118.55 |
| Enterprise Value to EBIT | -368.05 |
| Enterprise Value to Net Income | -393 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 57.36%▼ 1.70% |
|---|---|
| Total Invested | $340.02M▲ 1.37% |
| Investors Holding | 133▼ 2.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending (e.g., Medicare/Medicaid). Its decisions on drug pricing, reimbursement policies, and corporate tax rates directly impact a biopharma company's future revenue and profitability.
This committee allocates actual federal spending, determining the funding levels for crucial agencies like the FDA and NIH, and federal healthcare programs (Medicare/Medicaid) which are major future payers for approved drugs.
This committee directly regulates the FDA and NIH, which are existential for a clinical-stage biopharmaceutical company through drug approval processes and research funding, making it a primary regulatory body.
This committee's oversight of intellectual property (IP) law is critically important for a biopharmaceutical company, as patents protect its drug candidates and pipeline, directly impacting asset valuation.